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Summary 
The B7-CD28/CTLA-4 costlmulatory pathway can pro- 
vide a signal pivotal for T cell activation. Signaling 
through this pathway is complex due to the presence 
of two 87 family members, 87-l and 87-2, and two 
counterreceptors, CD28 and CTLA-4. Studies with 
anti-CTLA-4 monoclonal antibodies have suggested 
both positive and negative roles for CTLA-4 in T ceil 
activation. To elucidate the in vivo function of CTLA-4, 
we generated CTLA4-deficient mice. These mice rap 
idly develop lymphoproiiferative disease with multior- 
gan lymphocytic infiltration and tissue destruction, 
with particularly severe myocarditls and pancreatitis, 
and die by 3-4 weeks of age. The phenotype of the 
CTLA-Gdeflcient mouse strain is supported by studies 
that have suggested a negative role for CTLA-4 in T 
cell activation. The severe phenotype of mice lacking 
CTLA-4 implies a critical role for CTLA-4 in down- 
regulating T cell activation and maintaining lmmuno- 
logic homeostasis. In the absence of CTLA-4, periph- 
eral T cells are activated, can spontaneously proliferate, 
and may mediate lethal tissue injury. 
Introduction 
The importance of the B7-CD28/CTLA4 pathway in vivo 
has been illustrated dramatically by studies indicating that 
blockade of this pathway can induce long-term graft sur- 
vival (Lenschow et al., 1992; Turka et al., 1992) and sup- 
press autoimmunity in rodents (Cross et al., 1995; Finck et 
al., 1994; Perrin et al., 1995). These findings have inspired 
great interest in the manipulation of this pathway for thera- 
peutic purposes. However, the presenceof multiple recep- 
tors and ligands in the pathway, together with the potential 
for both positive and negative signaling (Linsley et al., 
1992; Gribben et al., 1994; Sethna et al., 1994; Walunas 
et al., 1994; Kearny et al., 1995; Krummel and Allison, 
1995) indicates that additional insights are needed to ma- 
nipulate this key immunoregulatory pathway optimally. 
CTLA4 is a T cell surface glycoprotein that shares 31% 
amino acid identity with CD28 (Harper et al., 1991) and, 
most notably, the MYPPPY motif thought to be involved 
in binding to 87-l (CD80) (Peach et al., 1994) and 87-2 
(CD86)(Azumaet al., 1993; Freeman et al., 1993a, 1993b; 
Lenschow et al., 1993). Binding studies using a soluble 
form of CTLA4 or CD28, comprised of the extracellular 
domain of CTLA4 or CD28 and Fc portion of immunoglob- 
ulin G (IgG) (CTLA-419, CD28lg), indicate that CTLA4 can 
bind both 87-l and 87-2 with a lo- to 20-fold higher affinity 
than CD28 (Linsley et al., 1994). In contrast with CD28, 
CTLA-4 is not expressed on resting T cells, but rather is 
induced following T cell activation (Freeman et al., 1992; 
Waiunas et al., 1994) with CD8+ T cells expressing higher 
levels of CTLA4 than CD4+ T cells. There is 100% phylo- 
genetic conservation of the CTLA-4 cytoplasmic domain, 
suggesting a conserved signaling function (Harper et al., 
1991). In contrast, there is limited conservation between 
the cytoplasmic domains of CD28 and CTLA4 (Harper et 
al., 1991) although a PI-3 kinase binding motif is con- 
served (Schneider et al., 1995). While the costimulatory 
function of CD28 is well established (Boussiotis et al., 
1994; Freeman et al., 1993a; June et al., 1994), the func- 
tion of CTLA4 remains uncertain. Studies using anti- 
CTLA4 monoclonal antibodies (MAbs) indicate that 
CTLA4 MAb enhances proliferation of T cells stimulated 
with anti-CD3 and anti-CD28 (Linsley et al., 1992; Gribben 
et al. 1994; Walunas et al. 1994; Krummel and Allison, 
1995). Initially, this observation was interpreted to suggest 
that CTLA4 increased or sustained costimulation (Linsley 
et al., 1992). Recent studies using anti-human and murine 
CTLA4 MAbs, however, suggest that rather than deliv- 
ering a positive signal through CTLA-4, anti-CTlA4 MAbs 
may block transduction of negative effects triggered by 
CTLA4(Gribbenetal., 1994; Kearnyetal., 1995; Krummel 
et al., 1995; Walunas et al., 1994) and in some cases can 
actually transduce a negative effect (Gribben et al., 1994; 
Walunas et al., 1994). These studies suggest that CTLA4 
may function either by terminating an antigen-specific T 
cell proliferative response or by inducing apoptosis, lead- 
ing to T cell death. 
To evaluate the functional role of CTLA-4 in vivo, we 
generated mice deficient (-I-) in CTLA4 expression by 
gene targeting in embryonic stem (ES) cells (Thomas and 
Capecchi, 1987). Mice lacking CTLA4 develop spleno- 
megaly and lymphadenopathy, multiorgan lymphocytic in- 
filtration and tissue destruction, and die by 3-4 weeks 
of age. This rapidly lethal phenotype strongly supports a 
critical role for CTLA4 in down-regulating T cell activation 
and maintaining immunologic homeostasis. 
Results and Discussion 
Generation of CTLA-CDeficient Mice 
We used gene targeting in embryonic stem (ES) cells to 
create mice lacking CTLA4 expression. Our targeting vec- 
tor replaced sequences encoding the IgV-like exon and a 
portion of the transmembrane exon of CTLA4 with the 
neomycin drug resistance gene (neo), which should effec- 
tively destroy CTLA-4 binding to 67-l and 87-2 (Peach 
et al., 1994) (Figure 1A). Germline-transmitting chimeric 
mice generated from targeted ES cells were bred to 
C57BU6 or BALBlc mice and progeny heterozygous for 
the CTLA4 mutation were interbred. Genotyping of prog- 
eny resulting from an intercross of two heterozygotes 
yielded the expected three types of progeny (Figure 1 B). 
CTLA4 deficiency resulted in a lethal phenotype, with 
death occurring by approximately 3-4 weeks of age. When 
anti-CD3-stimulated spleen cells from wild-type and 
CTLA4 -I- mice were stained for CTLA4 using anti- 
CTLA4 MAb (Walunas et al., 1994) expression was only 
observed in CTLA4 +I+ cells, confirming a lack of CTLA4 
expression (Figure 1C). 
Phenotype of Lymphocytes in CTLA-4 -I- Mice 
Because of the lethal phenotype, we carried out our stud- 
ies in 15 to 20-day-old mice. CTLA4 -I- thymuses were 
comparable in size to wild type, but exhibited a marked 
decrease (approximately 1 O-fold) in the percentage of dou- 
ble-positive CD4+CD6+ thymocytes and a relative increase 
in single-positive CD3+CD4+ and CD3+CD6+ T ceils as 
compared with wild-type mice (Figure 2). In addition, there 
was a 5-fold increase in CD4-CD6- cells in CTLA-4 -/- 
thymuses. This abnormal thymic composition could re- 
flect abnormal maturation of thymocytes. Alternatively, 
these findings could be the result of infiltration of the thy- 
mus by T cells from the periphery. CTLA4 -I- mice exhib- 
ited massive splenomegaly and lymphadenopathy with 
150-200 x 1 O6 lymph node cells being routinely obtained 
from CTLA4 -I- mice, as compared with 20 x lo6 from 
wild-type mice (n = 6). Flow cytometric analysisof CTLA4 
-I- spleen and lymph node cells revealed an increase in 
the percentage and absolute number of CD3+ cells and a 
proportional reduction in B220+ cells. The ratios of splenic 
and lymph node CD3+CD4+ and CD3+CD6+ cells was nor- 
mal. There was a marked increase in both the percentage 
and levels of expression of the activation markers CD69, 
CD25, and CD44 on T cells in CTLA4 -I- spleen and 
lymph nodes (Figure 2). In addition, forward scatter analy- 
sis indicated that CTLA-4 -I- T cells were larger than 
wild-type cells (data not shown). Especially striking was 
the reduction in Mel-14+ (naive) T cells in the spleen and 
lymph node of CTLA4 -I- mice, with a two-thirds reduc- 
tion in the number of Mel-14+ cells and a 3-fold reduction 
in mean fluorescence of Mel-14 on CTLA4 -I- cells. 
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Histologic and lmmunohistologic Analysis 
of CTLA4 -I- Mice 
Microscopic analysis revealed multiorgan mononuclear in- 
filtrates in CTLA4 -/- mice. There was a destructive myo- 
carditis with a massive interstitial infiltrate of lymphocytes, 
macrophages, and neutrophils, and a severe pancreatitis 
characterized by an intense mononuclear infiltrate with 
destruction of both islets and glandular elements (Figure 
3). lmmunohistochemical studies revealed that inflamma- 
tory infiltrates in the heart and pancreas consisted of abun- 
dant CD3+ cells, with a mix of CD4+ and CD6+ cells, as 
well as many F4/60+ macrophages and occasional B220+ 
B cells (Figure 3). The lungs and salivary glands also had 
interstitial mononuclear infiltrates and the liver exhibited 
abnormal aggregates of mononuclear cells in the absence 
of tissue destruction. In some mice, synovitis and vas- 
culitis were also observed. Interestingly, certain organs, 
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Figure 1. Targeting of the CTLA-4 Gene by Ho- 
mologous Recombination 
(A) Schematic representation of the gene- 
targeting vector used to disrupt the CTLA-4 
gene. Stippled boxes represent exons, and re- 
striction sites are indicated. 
(B) PCR analysis of tail DNA for the presence 
of the neomycin gene and the CTLA-4 IgV-like 
exon was used to genotype progeny of hetero- 
zygote interbreeding. Homozygous offspring 
were present at the expected Mendelian fre- 
quency. +I+, wild-type; +I-, heterozygous mu- 
tant; -I-, homozygous mutant; M, 100 bp 
markers. 
(C) Analysis of CTLA-4 expression in CTtA-4 
-I- mice by fluorescence-activated cell sorting 
(FACS) analysis. Splenocytes were stimulated 
with anti-CD3 for 48 hr. Cells were then doubly 
stained for CDS and CTLA-4 expression, and 
analyzed by flow cytometry. Data is gated for 
CDS+ cells. Thick line represents antiCTtA4 
MAb (4FlO) staining (Walunas et al., 1994) and 
thin line represents negative control hamster 
antibody. 
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such as the kidney and thyroid, exhibited no inflammatory 
changes. 
Analysis of CTLA4 -I- T Cell Function In Vitro 
Because of the marked lymphoproliferation and lympho- 
cytic infiltration in CTLA4 -I- mice, we were interested 
in the functional capabilities of CTLA-4 -I- T cells. We 
observed vigorous spontaneous proliferation of lymph 
node cells in culture and moderate spontaneous prolifera- 
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tion of spleen cells(Figure4). When these cells were evalu- 
ated after 6 days of culture, approximately 80% were 
CD4+CD8- and 20% were CD4CD8’. No spontaneous 
proliferation was observed in normal littermate controls. 
The proliferation of both wild-type and CTLA4 -I- lymph 
node cells and spleen cells was increased by the addition 
of asubmaximal concentration of anti-CD3 (1 pg/ml). Anal- 
ysis of tissue culture supernatants from anti-CD3-stim- 
ulated spleen and lymph node cells revealed that the 
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Figure 2. Flow Cytometric Analysis of Thymocytes, Splenocytes, and Lymph Node Cells from CTLA-4 -I- and Wild-Type Mice 
(A) Comparison of CD4’ versus CD8’ profile of thymocytes double-stained with anti-CDB-FITC and anti-CD4-PE. Percent cells in each quadrant 
are indicated. 
(B and C) Comparison of expression of activation markers on wild-type and CTLA4 -I- splenocytes (6) and lymph node cells (C). Animals whose 
cell analysis are shown were 16 days of age. Results are representive of four independent experiments. 
Figure 3. Myocarditis and Pancreatitis in CTtA-4 -I- Mice 
Heart tissue from wild-type mice ([A], original magnification, 50x) and CTiA-4 -I- mice ([G] and [Cl, original magnifications, 50x and 100x, 
respectively), are shown for comparison and to illustrate the fulminant inflammatory infiltrate that was characteristic of CTtA4 -/- mice. Pancreatic 
tissue from wild-type mice ([D], original magnification 50 x) and CTLA4 -I- mice ([E] and [F], original magnifications, 50 x and 100 x , respectively) 
are shown for comparison and to demonstrate the intense inflammatory infiltrate and destruction of islet and glandular elements typically observed 
in CTLA-4 -I- mice. lmmunohistochemical characterization of the cardiac (G-l) and pancreatic (J-L) inflammatory infiltrate for 8220’ cells (G, J), 
CD3’ cells (H, K), and F4/80’ cells (I, L) revealed that CD3’ and F4/80’ cells predominated in the mononuclear infiltrate. 
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Figure 4. CTLA-4 -I- Cells Can Proliferate 
Spontaneously and Produce Cytokines 
Proliferation of unstimulated and anti-CD3 
stimulated wild-type and CTfA-4 -/- spleen 
and lymph node cells at 72 hr is shown. Assays 
of IL-2 by ELBA in culture supernatants har- 
vested at 24 hr and the assays of IFNy, IL-4, 
and GM-CSF by ELISA at 48 hr are shown. 
Results are representative of three experi- 
ments. 
CTLA4 -I- cells produced markedly increased amounts 
of interferon y (IFN-r), interleukin 4(IL-4) and granulocyte- 
macrophage colony-stimulating factor (GM-CSF) as com- 
pared with cells from normal mice (Figure 4). GM-CSF 
also was produced by unstimulated CTLA4 -I- lymph 
node and spleen cells (Figure 4). All of these results indi- 
cate that T cells from CTLA4 -I- mice are activated in 
vivo, in the absence of overt stimulation by administered 
antigens. The hyperresponsiveness of CTLA-4 -I- lym- 
phocytes in vitro is not surprising in view of their activated 
phenotype (Mel-14r0, CD25h’, CD69”‘). 
The phenotype of CTLA+deficient mice demonstrates 
an unexpected spontaneous lymphoproliferative disease 
with lymphocytic infiltrates in many tissues, including the 
heart, and early lethality. In vivo splenomegaly and lymph- 
adenopathy develop, and in vitro CTLA-4-I- lymph node 
cells can spontaneously proliferate and produce cytok- 
ines. The severe phenotype of mice lacking CTLA4, in 
conjunction with several recently published studies using 
anti-CTLA-4 MAbs that have suggested a negative role 
forCTLA-4(Gribbenetal., 1994; Kearnyetal., 1995; Krum- 
mel and Allison, 1995; Walunas et al., 1994), strongly im- 
plies a down-regulatory role of CTLA4 in T cell activation. 
The observed lymphoproliferation could result from the 
failure to delete potentially autoreactive cells in the thy- 
mus, the failure to terminate an antigen-specific T cell 
proliferative response, or the failure of antigen-specific 
apoptosis of activated T lymphocytes. 
The severe phenotype further suggests a critical role 
for CTLA4 in regulating T cell activation and maintaining 
immunologic homeostasis, since in its absence, the major- 
ityofTcellsappearto beactivated. Thesefindingssuggest 
that CD28 and CTLA4 have opposing effects, and that 
the outcome of an immune response involves a balance 
between CD2Smediated T cell activation and CTLA-4- 
mediated down-regulation. The impressive lymphopro- 
liferation in these mice raises the question of whether 
CTLA4 functions to down-regulate T cells activated through 
other costimulatory pathways as well as through CD28 
Interbreeding of our mouse strain lacking both 87-l and 
87-2 with the CTLA-4 -I- strain is in progress and should 
resolve this issue. 
The CTLA-4 -I- strain provides a unique model of 
multisystem T cell-mediated disease, probably autoim- 
mune in nature. The severely destructive myocarditis and 
pancreatitis accompanied by large T cell infiltrates are 
consistent with autoimmune tissue destruction. The ab- 
normal thymic phenotype of CTLA4 -I- mice is striking, 
and may reflect abnormal lymphocyte development in 
CTLA-4 -I- mice. It may be that thymic deletion does not 
occur appropriately in CTLA-4 -I-, resulting in the escape 
of self-reactive T cells into the periphery. Interestingly, the 
B7 costimulatory molecules are expressed in the thymus 
and CD28 is expressed on thymocytes (Nelson et al., 
1993). While these data might suggest a role for CD28-B7 
interactions in thymic deletion, CD28deficient mice are 
capable of deleting Mlsla-reactive Vf33 T cells (J. A. B. 
et al., unpublished data). Therefore, it may be that CTLA4, 
rather than CD28, could play a role in thymic deletion. It 
has been difficult to assess directly the role of CTLA4 in 
lymphocyte development, since blocking CD28 signaling 
via CTLA-4lg also prevents CTLA4 expression (Walunas 
et al., 1994). 
Alternatively, the observed thymic imbalance could re- 
flect infiltration of the thymus by single-positive cells from 
the periphery. Such infiltration, together with the presence 
of numerous T cells in areas of tissue damage, would be 
consistent with a peripheral CTLA+dependent regulatory 
mechanism. If this were the case, then CTLA4 would func- 
tion to down-regulate T cells continuously in the periphery 
following antigen exposure or delete autoreactive T cells 
in the periphery that have not been deleted in the thymus. 
This hypothesis is consistent with the studies of Gribben 
et al. (1994) suggesting that CTLA4 triggers antigen- 
specific apoptosis, leading to T cell death. 
While additional studies are needed to distinguish be- 
tween these alternatives, the striking phenotype of the 
CTLA4 -I- mice supports an important role for CTLA-4 
in preventing activation of autoimmune responses. CTLA- 
4-mediated regulation of autoreactive T cells would appear 
to be critical for a balanced immune system, as demon- 
strated by the rapidly lethal phenotype of the CTLA-4 -I- 
mouse strain. The phenotype of the CTLA-4 -I- strain also 
has therapeutic implications, suggesting that triggering 
CTLA-4 could provide a means to regulate activated T 
cells mediating autoimmune diseases and graft rejection. 
Our findings further suggest that the use of CTLA-4lg to 
block B7-mediated T cell activation may be complex, since 
CTLA-4lg could block both CD28-mediated costimulation 
and CTLA4-mediated inhibitory effects. 
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Experimental Procedures 
Homologous Recombination Construct and Targetlng of ES Cells 
PI clones containing murine CTLA-4 sequence were identified by 
screening a 129 ES ceil genomic library with a poiymerase chain reac- 
tion (PCR) primer pair spanning the IgV-like encoding exon 2. Two 
distinct clones were obtained from Genome Systems, Incorporated (St. 
Louis, Missouri). The PI clones were subcloned into pBluescript-pKSIi 
(Stratagene, La Jolla, California) for subsequent manipulation. The 
targeting vector described in Figure IA was generated by replacing 
a 1.3 kb region encompassing the IgV-like exon 2 and a portion of 
exon 3 (from Hindtil to Barn HI) with neo driven by the mouse phospho- 
glycerol kinase (PGK) promoter (McBurney et al., 1991) and linked 
to the PGK poly(A) sequences. To select against random insertional 
events, a thymidine kinase (r&) gene under the regulation of the MCI 
promoter was incorporated at the 3’end of the targeting vector (Man- 
sour et al., 1968; Thomas and Capecchi, 1967; Zijlstra et al., 1990). 
The recombination vector contained 3 kb and 4 kb of homology up- 
stream and downstream, respectively, of the PGK-neo gene and the 
pMC rk kinase gene at its most B’end. The recombination vector was 
incorporated into Jl ES cells (Li et al., 1992) maintained on subcon- 
fluent embryonic fibroblasts. Neomycin- and FIAU-resistant ES cell 
colonies were picked and expanded. DNA was prepared and analyzed 
by Southern blotting using DNA probes from outside the homologous 
recombination area, as depicted in Figure IA. Single integration 
events were scored using a probe derived from the neo gene. Three 
distinct ES cell lines heterozygous for the mutation were microinjected 
into blastocysts from C57BU6 and BALBlc mice, and gave rise to 
germline transmission of the CTLA-4 mutation. Mice heterozygous for 
the CTLA-4 mutation were interbred. The genotype of progeny was 
determined by PCR analysis of tail DNA using primers for the neo 
gene (Freeman et al., 1993c) and primers specific for the CTLA4 
IgV-like exon (sense, 5’ TGG TGT TGG CTA GCA GCC ATG 3’; anti- 
sense, STTGGATGGTGAGGTTCACTC3’)Tail DNAwassubjected 
to 30 cycles of amplification at 94OC for 1 min, at 58OC for 1 min, and 
at 72OC for I min followed by a 10 min extension at 72OC. The resulting 
PCR products were eiectrophoresed on a 1.2% agarose, 0.5 x TBE 
gel. The results reported here have been observed with three indepen- 
dent clones, which gave germiine transmission. 
Histological and lmmunohistologicai Analysis 
of CTLA-4 Mutant Mice 
Tissue for light microscopy was fixed in 10% buffered formalin, pro- 
cessed, and embedded in paraffin. Sections were stained with hema- 
toxylin and eosin using standard techniques. 
Fresh frozen sections were cut, acetone-fixed, incubated with pri- 
mary anti-CD3 (299) anti-B220/CD45 (692) or anti-F4/80 MAbs, 
followed by biotinylated anti-rat (Vector Laboratories, Incorporated, 
Buriingame, California) and streptavidin peroxidase (Biogenex, San 
Ramon, California) as described (Lynch et al., 1995). Diaminobenzi- 
dine was used as the chromagen. 
Cell Surface Staining 
Thymtts, spleen, and lymph node ceils were stained with a panel of 
fluorochrome-conjugated antibodies, including fluorescein isothiocya- 
nate (FITC)conjugated and phycoerythrin (PE)-conjugated anti-CDS, 
anti-9220, antiCD4, and antiCD8. To assess the state of activation 
of ceils, double-staining with a pool of FITC- and PE-conjugated isotype 
controls, anti-CD69-FITClanti-CD3-PE, anti-CD25-FITClanti-CD3- 
PE, anti-CD3-FITClanti-CD44-PE, or anti-CD3-FITClanti-Mel-l4-PE 
was performed. All of these antibodies were purchased from Phar- 
mingen (San Diego, California). Stained cells were analyzed on a FAC- 
STAR plus (Becton Dickinson, Mountain View, California). 
To analyze the expression of CTLA-4, splenocytes from CTLA-4 
-I- mice or wild-type mice were incubated with 10 uglml of anti-CD3 
and harvested 48 hr poststimulation and stained for CD8 versus 
CTLA4 using FITC-conjugated 4FlO antiCTLA4 MAb (Walunas et al., 
1994) or isotype-matched hamster control MAb and PE-conjugated 
antiCD8. 
Cell Preparations and Cultures 
Cell suspensions from thymus, spleen, and lymph nodes were pre- 
pared by grinding tissue through sterile wire mesh. To assay prolifera- 
tive responses, 2 x 105 spleen or lymph node ceils were cultured in 
plating media alone (RPM1 supplemented with 10% heat-inactivated 
fetal calf serum; Sigma, St. Louis, Missouri), 5 x IO” M P-mercap 
toethanol, 2 mM L-glutamine, 100 Kg/ml penicillin, 250 ng/mi strepto- 
mycin, 15 us/ml gentamycin, 10 mM HEPES (ail from GIBCO, Grand 
Island, New York), or stimulated in plating media containing anti-CD3 
(2Cll) at 1 pglml. Cells were pulsed for the final 16 hr of a 72 hr 
incubation with PH]thymidine (New England Nuclear, Boston, Massa- 
chusetts). incorporated radioactivity was measured by liquid scintiiia- 
tion counting. 
Cytokine Assays 
To measure cytokine secretion, culture supernatants were collected 
at 24 hr (to measure IL-2 and GM-CSF) and 48 hr (to measure IFNT, 
11-4, and GM-CSF) and assayed by enzyme-linked immunosorbent 
assay(ELISA)(lL-2and IL4MAbs, Pharmingen, San Diego, California; 
GM-CSF, Endogen, Cambridge, Massachusetts; IFNT, Genzyme, 
Cambridge, Massachusetts), according to the instructions of the manu- 
facturer. Cytokine levels were determined using a standard curve, 
which was linear down to the lower limit of detection. 
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